RDG Stock Overview
Engages in the detection, prevention, and treatment of various types of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Read-Gene S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł4.74 |
| 52 Week High | zł7.80 |
| 52 Week Low | zł2.70 |
| Beta | -1.17 |
| 1 Month Change | -14.75% |
| 3 Month Change | -5.20% |
| 1 Year Change | 48.13% |
| 3 Year Change | 49.06% |
| 5 Year Change | 426.67% |
| Change since IPO | 75.56% |
Recent News & Updates
Shareholder Returns
| RDG | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -0.8% | -2.1% | -2.7% |
| 1Y | 48.1% | -18.1% | 24.5% |
Return vs Industry: RDG exceeded the Polish Biotechs industry which returned -18.1% over the past year.
Return vs Market: RDG exceeded the Polish Market which returned 24.5% over the past year.
Price Volatility
| RDG volatility | |
|---|---|
| RDG Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PL Market | 9.2% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: RDG has not had significant price volatility in the past 3 months.
Volatility Over Time: RDG's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 27 | Jan Lubinski | www.read-gene.com |
Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer. Its activities include chemoprevention, clinical tests, and genetic tests. Chemoprevention is the use of natural or synthetic substances to stop, reverse, or delay the process of developing cancer.
Read-Gene S.A. Fundamentals Summary
| RDG fundamental statistics | |
|---|---|
| Market cap | zł55.88m |
| Earnings (TTM) | -zł1.94m |
| Revenue (TTM) | zł10.66m |
5.2x
P/S Ratio-28.9x
P/E RatioIs RDG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDG income statement (TTM) | |
|---|---|
| Revenue | zł10.66m |
| Cost of Revenue | zł1.03m |
| Gross Profit | zł9.63m |
| Other Expenses | zł11.57m |
| Earnings | -zł1.94m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 12, 2024
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 90.32% |
| Net Profit Margin | -18.15% |
| Debt/Equity Ratio | 177.6% |
How did RDG perform over the long term?
See historical performance and comparison